Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice

Riferimento: 
Tumour Biol. 2012 Feb;33(1):229-39.
Autori: 
Oddstig J, Bernhardt P, Lizana H, Nilsson O, Ahlman H, Kölby L, Forssell-Aronsson E.
Fonte: 
Tumour Biol. 2012 Feb;33(1):229-39.
Anno: 
2012
Azione: 
L'attività nei tumori neuroendocrini di 177Lu-DOTA0-Tyr3-octreotide ha mostrato una concentrazione minore nella parte periferica rispetto alla parte centrale del tumore.
Target: 
177Lu-DOTA0-Tyr3-octreotide/tumori neuroendocrini.

ABSTRACT
The aim of this study was to investigate the activity distribution in neuroendocrine tumors after diagnostic, or therapeutic, amounts of [(177)Lu-DOTA(0)-Tyr(3)]-octreotate and to investigate how the activity distribution influences the absorbed dose. Furthermore, the activity distribution of a second administration of radiolabeled octreotate was studied. Nude mice with subcutaneously grown human midgut carcinoid (GOT1) were injected intravenously with different amounts of (177)Lu-octreotate. At different time points thereafter (4 h to 13 days), a second injection of [(111)In-DOTA(0)-Tyr(3)]-octreotate was given to estimate the somatostatin receptor (sstr) expression. The activity distribution in the tumors was then determined. Monte Carlo simulations with PENELOPE were performed for dosimetry. Fifty-one out of 58 investigated tumors showed a lower activity concentration in the peripheral part than in the central part of the tumor. The amount of activity injected, or time after administration, did neither influence the relative activity nor the sstr distribution in the tumor. After an initial down-regulation (at 4-24 h), there was an up-regulation of sstr (1.5-2 times, at 7-14 days). Monte Carlo simulations demonstrated an inhomogeneous absorbed dose distribution in the tumor using (177)Lu, with twice as high absorbed dose centrally than peripherally. The high activity concentration centrally and the up-regulation of sstr demonstrated will facilitate fractionated therapy using radiolabeled somatostatin analogues if similar results will be obtained also in patients. The inhomogeneous activity distribution in the tumor has to betaken into account when the absorbed dose distribution in tumor is calculated.